Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 14Neoplasm Metastasis 12Carcinoma, Medullary 12Neoplasms 10Thyroid Neoplasms 8Breast Neoplasms 8Glioma 6Prostatic Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Gliosarcoma 4Colorectal Neoplasms 4Brain Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2Recurrence 2Rectal Neoplasms 2Pleural Effusion 2Kidney Neoplasms 2Familial medullary thyroid carcinoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Disease Progression 2

Interventions

pembrolizumab 92Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 24Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × vandetanib × Clear all
NCT00880334 2018-09-18

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

Dana-Farber Cancer Institute

Phase 2 Completed
149 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡